The Future of Medical Cannabis in France: Current Situation and Outlook for 2025
Introduction
Medical cannabis is a topic generating increasing interest in France, both among healthcare professionals and patients. In 2024, as the medical cannabis experimentation draws to a close, attention turns to 2025, the year when the first cannabis-based medicines are expected to be available on the market. This article explores the current regulatory landscape, the laboratories involved in developing these medicines, and introduces Chanvrery CBD Shop, your go-to for high-quality CBD products.
Current Situation: Medical Cannabis Experimentation
Since the launch of the experimentation in March 2021, several thousand patients have benefited from cannabis-based treatments for conditions such as:
- Refractory neuropathic pain
- Pharmaco-resistant epilepsies
- Oncology-related symptoms
- Painful spasticity associated with multiple sclerosis
The National Agency for the Safety of Medicines and Health Products (ANSM) oversaw this experimentation, which was extended until December 31, 2024. Preliminary results indicate promising efficacy and an acceptable safety profile, paving the way for future commercialization.
Laboratories and Drug Development
Several French laboratories are currently involved in the research and development of cannabis-based medicines. Among them:
- Biophytis: Specializes in innovative treatments based on plant extracts.
- Cannabics Pharmaceuticals: Known for its research on cannabinoids and their therapeutic use.
- Eurapharma: Active in the distribution of cannabis-based medicines.
These companies work closely with the ANSM to ensure that products meet the required safety and efficacy standards before market release.
Outlook for 2025
In 2025, France is expected to see the arrival of the first cannabis-based medicines on the market. This development will require:
- Clear regulation: The 2024 social security financing law provides for temporary authorization for the use of cannabis-based medicines for a period of five years.
- Healthcare professional awareness: It will be crucial to inform doctors about the new therapeutic options available.
- Facilitated patient access: Efforts will be needed to ensure these treatments are accessible to patients who need them.
Chanvrery CBD Shop: Your Reference for CBD Products
At Chanvrery CBD Shop, we are proud to offer a varied range of CBD products, including CBD, CBG, and CBN oils, all rigorously selected for their exceptional quality. Our products are:
- THC-free certified: To ensure safe use.
- Lab-tested: Ensuring purity and effectiveness.
- Offered at competitive prices: Making well-being accessible to all.
Why Choose Chanvrery?
- Local expertise: Our team consists of passionate professionals who will guide you in choosing products tailored to your needs.
- Diverse products: Whether you are looking for soothing oils or aromatic CBD flowers, we have what you need.
Conclusion
The landscape of medical cannabis in France is rapidly evolving. With the imminent end of the experimentation and the anticipated arrival of cannabis-based medicines in 2025, it is essential to be informed about future developments. At Chanvrery CBD Shop, we are committed to providing you with superior quality CBD products that meet the growing market needs.For more information or to discover our complete range, do not hesitate to visit us or contact us!📍 Chanvrery CBD Shop
📞 Phone: [0987356232]
🕙 Hours: (7 days a week)
Sources:
- ANSM - Medical cannabis: progress report on the experimentation.
- LaFleur - Overview of medical cannabis in France.
- Ordre National des Pharmaciens - Continuity in the medical cannabis experimentation.
Leave a comment